{"id":20220,"date":"2024-08-03T21:58:03","date_gmt":"2024-08-03T19:58:03","guid":{"rendered":"https:\/\/tirzepatyd.eu\/?post_type=product&#038;p=20220"},"modified":"2026-05-03T21:42:48","modified_gmt":"2026-05-03T19:42:48","slug":"tirzepatide-pen-10-mg","status":"publish","type":"product","link":"https:\/\/tirzepatyd.eu\/en\/shop-product\/tirzepatide-pen-10-mg\/","title":{"rendered":"GLP1+GIP PEN 10 mg."},"content":{"rendered":"<div data-elementor-type=\"product-post\" data-elementor-id=\"20220\" class=\"elementor elementor-20220\" data-elementor-post-type=\"product\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-82c1bc5 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"82c1bc5\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-edd1509\" data-id=\"edd1509\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7597d2d elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"7597d2d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2 data-start=\"66\" data-end=\"117\">Tirzepatide Pen 10 mg - characteristics<\/h2><p data-start=\"119\" data-end=\"376\"><strong data-start=\"119\" data-end=\"144\">Tirzepatide pen 10 mg<\/strong> refers to the formulation used in clinical trials of the synthetic peptide analogue tirzepatide. The substance is a dual agonist of GIP and GLP-1 receptors and belongs to the modified incretin peptides.<\/p><p data-start=\"378\" data-end=\"725\">Thirzepatide is a molecule composed of 39 amino acids whose structure was designed to increase metabolic stability and prolong duration of action. It contains modifications that limit enzymatic degradation and a lipid component that allows reversible binding to albumin. The molecular weight of the compound is approximately 4813 Da.<\/p><p data-start=\"727\" data-end=\"930\">In a laboratory context, the term <em data-start=\"766\" data-end=\"783\">Tirzepatide pen<\/em> refers to the delivery system used in the study, while the molecule itself remains the subject of pharmacological and molecular analyses.<\/p><hr data-start=\"871\" data-end=\"874\" \/><h2 data-start=\"876\" data-end=\"937\">Thirzepatide pen - mechanism of action (molecular approach)<\/h2><p data-start=\"939\" data-end=\"1097\">The mechanism of action of tirzepatide pen 10 mg is due to the properties of the tirzepatide molecule itself as an agonist of incretin receptors belonging to the GPCR family.<\/p><h3 data-start=\"1099\" data-end=\"1137\">Activation of GIP and GLP-1 receptors<\/h3><p data-start=\"1138\" data-end=\"1306\">Tirzepatide pen exhibits the ability to simultaneously activate GIPR and GLP-1R. The synergistic effect of this dual activity was analyzed in clinical studies:<\/p><ul><li data-start=\"1310\" data-end=\"1346\">glucose-dependent insulin secretion,<\/li><li data-start=\"1349\" data-end=\"1383\">inhibition of glucagon secretion,<\/li><li data-start=\"1386\" data-end=\"1415\">Regulation of glucose homeostasis.<\/li><\/ul><h3 data-start=\"1417\" data-end=\"1451\">Effect on gastric emptying<\/h3><p data-start=\"1452\" data-end=\"1607\">In clinical models, tirzepatide pen 10 mg was associated with slowed gastrointestinal motility, which correlated with prolonged gastric emptying time.<\/p><h3 data-start=\"1609\" data-end=\"1652\">Modulation of central satiety pathways<\/h3><p data-start=\"1653\" data-end=\"1833\">GLP-1 receptors are present in structures of the central nervous system. The study evaluated the effects of tirzepatide pen on signals related to the regulation of appetite and energy balance.<\/p><h3 data-start=\"1835\" data-end=\"1863\">Metabolic parameters<\/h3><p data-start=\"1864\" data-end=\"2056\">Clinical data on tirzepatide pen included analysis of changes in body weight, glycemic indices and lipid parameters in relation to dose (5 mg, 10 mg, 15 mg) and follow-up time.<\/p><hr data-start=\"2058\" data-end=\"2061\" \/><h2 data-start=\"2063\" data-end=\"2105\">Tirzepatide pen in clinical trials<\/h2><p data-start=\"2107\" data-end=\"2305\">One of the most cited research projects is <strong data-start=\"2165\" data-end=\"2206\"><span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">SURMOUNT-1<\/span><\/span><\/strong>, which evaluated the effect of tirzepatydu in subjects in a research protocol who were overweight or obese.<\/p><p data-start=\"2307\" data-end=\"2519\">The 72-week follow-up showed statistically significant differences from placebo in terms of dose-dependent changes in body weight on a weekly schedule. Tirzepatide pen was also analyzed for:<\/p><ul data-start=\"2521\" data-end=\"2629\"><li data-start=\"2521\" data-end=\"2537\"><p data-start=\"2523\" data-end=\"2537\">HbA1c changes,<\/p><\/li><li data-start=\"2538\" data-end=\"2568\"><p data-start=\"2540\" data-end=\"2568\">fasting glucose levels,<\/p><\/li><li data-start=\"2569\" data-end=\"2592\"><p data-start=\"2571\" data-end=\"2592\">lipid profile,<\/p><\/li><li data-start=\"2593\" data-end=\"2629\"><p data-start=\"2595\" data-end=\"2629\">cardio-metabolic parameters.<\/p><\/li><\/ul><p data-start=\"2631\" data-end=\"2740\">Separate phase 3 studies compared tirzepatide with other GLP-1 agonists in a population with type 2 diabetes.<\/p><hr data-start=\"2742\" data-end=\"2745\" \/><h2 data-start=\"2813\" data-end=\"2861\">Safety and side effects - data reported in studies<\/h2><p data-start=\"2805\" data-end=\"2932\">In clinical trials for tirzepatide pen 10 mg, gastrointestinal symptoms were most commonly reported, including:<\/p><ul><li data-start=\"2936\" data-end=\"2947\">nausea,<\/li><li data-start=\"2950\" data-end=\"2960\">vomiting,<\/li><li data-start=\"2963\" data-end=\"2974\">diarrhea,<\/li><li data-start=\"2977\" data-end=\"2988\">constipation,<\/li><li data-start=\"2991\" data-end=\"3008\">feeling of fullness.<\/li><\/ul><p data-start=\"3010\" data-end=\"3203\">The incidence of adverse effects was dose and escalation phase dependent. These data are from controlled clinical trials and remain subject to further long-term analysis.<\/p><hr data-start=\"3205\" data-end=\"3208\" \/><h2 data-start=\"3210\" data-end=\"3234\">Research application<\/h2><p data-start=\"3236\" data-end=\"3301\">In a laboratory context, the tirzepatide pen is treated as:<\/p><ul><li data-start=\"3305\" data-end=\"3346\">A model GIP\/GLP-1 receptor agonist,<\/li><li data-start=\"3349\" data-end=\"3392\">GPCR signaling research tool,<\/li><li data-start=\"3395\" data-end=\"3474\">reference compound in analyses of glucose metabolism and energy regulation.<\/li><\/ul><p data-start=\"3476\" data-end=\"3603\">The product is intended for research and analytical applications only.<br data-start=\"3548\" data-end=\"3551\" \/>It is not a dietary supplement or food product.<\/p><p data-start=\"3476\" data-end=\"3603\"><a href=\"https:\/\/tirzepatyd.eu\/de\/shop-produkt\/slu-pp-332\/\">See also SLU-PP-332 60caps\/500mcg.<\/a><\/p><hr data-start=\"3605\" data-end=\"3608\" \/><h3><a href=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/10mg-PEN-Camera.png\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-30659 size-medium\" src=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/10mg-PEN-Camera-300x225.png\" alt=\"Tirzepatide Pen 10 mg GLP1 GIP peptide for weight loss europe\" width=\"300\" height=\"225\" srcset=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/10mg-PEN-Camera-300x225.png 300w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/10mg-PEN-Camera-800x600.png 800w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/10mg-PEN-Camera-64x48.png 64w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/10mg-PEN-Camera-768x576.png 768w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/10mg-PEN-Camera-16x12.png 16w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2025\/09\/10mg-PEN-Camera.png 1024w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/h3><div><p data-start=\"3610\" data-end=\"3627\">Scientific sources:<\/p><ol data-start=\"3629\" data-end=\"3989\"><li data-start=\"3629\" data-end=\"3799\"><p data-start=\"3632\" data-end=\"3799\">Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. <em data-start=\"3707\" data-end=\"3740\">New England Journal of Medicine<\/em>, 2022.<br data-start=\"3747\" data-end=\"3750\" \/>PubMed: <a class=\"decorated-link\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\" target=\"_new\" rel=\"noopener\" data-start=\"3758\" data-end=\"3799\">https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/<\/a><\/p><\/li><li data-start=\"3801\" data-end=\"3989\"><p data-start=\"3804\" data-end=\"3989\">Fr\u00edas JP et al. Thirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. <em data-start=\"3897\" data-end=\"3930\">New England Journal of Medicine<\/em>, 2021.<br data-start=\"3937\" data-end=\"3940\" \/>PubMed: <a class=\"decorated-link\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35579691\/\" target=\"_new\" rel=\"noopener\" data-start=\"3948\" data-end=\"3989\">https:\/\/pubmed.ncbi.nlm.nih.gov\/35579691\/<\/a><\/p><\/li><\/ol><hr data-start=\"3605\" data-end=\"3608\" \/><p><strong>Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.<\/strong><\/p><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p><strong data-start=\"91\" data-end=\"116\">Tirzepatide pen 10mg<\/strong> is a high-quality synthetic peptide with dual activity against GIP and GLP-1 receptors for advanced research projects on metabolism, body weight and regulation of energy homeostasis.<\/p>","protected":false},"featured_media":30659,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[122,111,15],"product_tag":[],"class_list":{"0":"post-20220","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-produkty-w-penie","7":"product_cat-glp1gip","8":"product_cat-laboratory-research","10":"first","11":"outofstock","12":"sale","13":"shipping-taxable","14":"purchasable","15":"product-type-simple"},"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/20220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/comments?post=20220"}],"version-history":[{"count":26,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/20220\/revisions"}],"predecessor-version":[{"id":35460,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/20220\/revisions\/35460"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/media\/30659"}],"wp:attachment":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/media?parent=20220"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_brand?post=20220"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_cat?post=20220"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_tag?post=20220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}